Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of remimazolam besylate to inhibit cardiovascular response to laryngeal mask insertion in elderly patients
ChiCTR2300067838Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in anesthesia induction, sponsored by Xijing Hospital. Primary endpoint: Dose of remimazolam. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
anesthesia induction
Beyond the preview
Go deeper on ChiCTR2300067838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067838.